Overview

A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Participants Who Are Obesity or Overweight

Status:
NOT_YET_RECRUITING
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy and safety of the oral small molecule MDR-001 Tablets over 52 weeks as an adjunct to a lifestyle intervention in participants with overweight or obesity.The goal of this clinical trial is to determine whether the oral drug MDR-001 can improve weight management in adult participants with overweight or obesity.
Phase:
PHASE3
Details
Lead Sponsor:
MindRank AI Ltd